Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-->Ile mutation in the amyloid precursor protein gene.
Alzheimer's disease (AD) is the most common cause of dementia (32). Although the majority of cases of AD are sporadic, the most consistent risk factor detected in several epidemiological studies has been a positive family history of the disease (14,21). In addition, many large pedigrees have been described in which AD appears to be inherited as an autosomal dominant disorder. In one such pedigree (F23) a point mutation within the beta-amyloid precursor protein (APP) gene at codon 717 was identified and hypothesized to be pathogenic (10). The mutation results in a valine to isoleucine change in APP (APP717 Val-->Ile). Subsequent screening has revealed four other pedigrees, detailed in this study, in which this mutation co-segregates with AD (13,26,37). In addition, one other pedigree (Tor3) with this mutation has been described (15) and detailed clinical, neuropsychological, and neuropathological data are reported. Tor3 is discussed below in comparison to the findings in the families in this study. The five families we report with the mutation were identified in Britain (1 family), the United States (1 family), and Japan (3 families). The mutation has not been reported in the general population of any of these countries (3,13,26,33). On this basis alone it seems this mutation is pathogenic. Other APP codon 717 mutations have been identified which co-segregate with the disease (4,25). Also, a double mutation in APP at codons 670/671 has been shown to cosegregate with the disease in two large Swedish pedigrees (22). In all cases, there is complete co-segregation of the APP mutation with early onset AD, providing overwhelming statistical evidence that these mutations are pathogenic. We present the clinical features and limited neuropathology of AD in these families with the APP 717 Val-->Ile mutation.
Mullan
M
M
Department of Psychiatry, University of South Florida, Tampa 33612.
Tsuji
S
S
Miki
T
T
Katsuya
T
T
Naruse
S
S
Kaneko
K
K
Shimizu
T
T
Kojima
T
T
Nakano
I
I
Ogihara
T
T
D000328:Adult; D017668:Age of Onset; D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D001921:Brain / Q000473:pathology; D001923:Brain Chemistry / Q000502:physiology; D002170:Canada; D003062:Codon / Q000235:genetics; D004314:Down Syndrome / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D007532:Isoleucine / Q000378:metabolism; D007564:Japan; D016631:Lewy Bodies / Q000648:ultrastructure; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010375:Pedigree; D006113:United Kingdom; D014481:United States; D014633:Valine / Q000378:metabolism
D016564:Amyloid beta-Protein Precursor; D003062:Codon; D007532:Isoleucine; D014633:Valine